Journal Mobile Options
Table of Contents
Vol. 16, No. 6, 2011
Issue release date: September 2011
Section title: Original Paper
Audiol Neurotol 2011;16:388–397
(DOI:10.1159/000322641)

Safety of Intratympanic Injection of AM-101 in Patients with Acute Inner Ear Tinnitus

Muehlmeier G. · Biesinger E. · Maier H.
aDepartment of ENT, Head and Neck Surgery, German Armed Forces Hospital Ulm, Ulm, and bENT Clinic and Otolaryngology Department of Klinikum Traunstein, Traunstein, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2010
Accepted: 2/11/2010
Published online: 1/21/2011

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 3

ISSN: 1420-3030 (Print)
eISSN: 1421-9700 (Online)

For additional information: http://www.karger.com/AUD

Abstract

Effective pharmacological treatments for tinnitus have proven elusive. Emerging evidence suggests that dysregulation of cochlear N-methyl-D-aspartate (NMDA) receptors may underlie aberrant excitation of the auditory nerve, which in turn is perceived as tinnitus. The blocking of these receptors thus represents a promising therapeutic approach. In a recent phase I/II clinical trial, the safety and local tolerance of intratympanic injections of the NMDA receptor antagonist AM-101 was evaluated for the first time in humans. The results from the double-blind, randomized, placebo-controlled study show that intratympanically injected AM-101 was well tolerated by study participants, and provided the first indications of therapeutic efficacy.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2010
Accepted: 2/11/2010
Published online: 1/21/2011

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 3

ISSN: 1420-3030 (Print)
eISSN: 1421-9700 (Online)

For additional information: http://www.karger.com/AUD


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Alzamil KS, Linthicum FH Jr: Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol 2000;109:30–32.
  2. Andersson G, Vretblad P, Larsen HC, Lyttkens L: Longitudinal follow-up of tinnitus complaints. Arch Otolaryngol Head Neck Surg 2001;127:175–179.
  3. Araújo MF, Oliveira CA, Bahmad FM: Intratympanic dexamethasone injections as a treatment for severe, disabling tinnitus: does it work? Arch Otolaryngol Head Neck Surg 2005;131:113–117.
  4. Biesinger E, Heiden C, Greimel V, Lendle T, Hoeing R, Albegger K: Strategies in ambulatory treatment of tinnitus. HNO 1998;46:157–169.
  5. Chan Y: Tinnitus: etiology, classification, characteristics, and treatment. Discov Med 2009;42:133–136.
  6. Chen Z, Duan M, Lee H, Ruan R, Ulfendahl M: Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in Guinea pigs. Audiol Neurotol 2003;8:49–56.
  7. Darlington CL, Smith PF: Drug treatments for tinnitus. Prog Brain Res 2007;166:249–262.
  8. Davis PB, Paki B, Hanley PJ: Neuromonics Tinnitus Treatment: third clinical trial. Ear Hear 2007;28:242–259.
  9. DeLucchi E: Transtympanic pilocarpine in tinnitus. Int Tinnitus J 2000;6:37–40.
  10. Dobie RA: A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202–1211.
  11. Dobie RA: Clinical trials and drug therapy for tinnitus; in Snow JB (ed): Tinnitus – Theory and Management. Hamilton, BC Decker, 2004, pp 266–277.
  12. Dodson K, Sismanis A: Intratympanic perfusion for the treatment of tinnitus. Otolaryngol Clin North Am 2004;37:991–1000.
  13. Eggermont JJ, Roberts LE: The neuroscience of tinnitus. Trends Neurosci 2004;27:676–682.
  14. Ehrenberger K: Topical administration of caroverine in somatic tinnitus treatment: proof-of-concept study. Int Tinnitus J 2005;11:34–37.
  15. Engström B, Bjurström S, Jansson B, Engström H, Angelborg C: An ultrastructural and functional study of the inner ear after administration of hyaluronan into the middle ear of the guinea pig. Acta Otolaryngol Suppl 1987;442:66–71.
  16. Greimel KV, Leibetseder M, Unterrainer J, Biesinger E, Albegger K: Der Tinnitus-Beeinträchtigungs-Fragebogen (TBF-12) – Übersetzung und Adaptation. Verhaltensther Verhaltensmed 2000;21:39–49.
  17. Guitton M, Dudai Y: Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma. Neural Plast 2007;2007:80904.
  18. Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL: Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003;23:3944–3952.
  19. Jastreboff PW, Hazell JWP, Graham RL: Neurophysiological model of tinnitus: dependence of the minimal masking level on treatment outcome. Hear Res 1994;80:216–232.
  20. Kemp JA, McKernan RM: NMDA receptor pathways as drug targets. Nat Neurosci 2002;5(suppl):1039–1042.
  21. Knipper M, Zimmermann U, Müller M: Molecular aspects of tinnitus. Hear Res 2010;266:60–69.
  22. Langguth B, Salvi R, Elgoyhen AB: Emerging pharmacotherapy of tinnitus. Expert Opin Emerg Drugs 2009;14:687–702.
  23. Lustig LR: The history of intratympanic drug therapy in otology. Otolaryngol Clin North Am 2004;37:1001–1017.
  24. Meikle MB, Stewart BJ, Griest SE, Henry JA: Tinnitus outcomes assessment. Trends Amplif 2008;12:223–235.
  25. Meikle MB, Stewart BJ, Griest SE, Martin WH, Henry JA, Abrams HB, McArdle R, Newman CW, Sandridge SA: Assessment of tinnitus: measurement of treatment outcomes. Prog Brain Res 2007;166:511–521.
  26. Mitchell JF: Intratympanic injection for tinnitus aurium. J Laryngol Otol 1950;64:576–579.
  27. Patterson MB, Balough BJ: Review of pharmacological therapy for tinnitus. Int Tinnitus J 2006;12:149–160.
  28. Puel JL, Ruel J, Guitton M, Wang J, Pujol R: The inner hair cell synaptic complex: physiology, pharmacology and new therapeutic strategies. Audiol Neurotol 2002;7:49–54.
  29. Quaranta A, Portalatini P, Henderson D: Temporary and permanent threshold shift: an overview. Scand Audiol Suppl 1998;48:75–86.
  30. Ruel J, Bobbin RP, Vidal D, Pujol R, Puel JL: The selective AMPA receptor antagonist GYKI 53784 blocks action potential generation and excitotoxicity in the guinea pig cochlea. Neuropharmacology 2000;39:1959–1973.
  31. Ruel J, Wang J, Rebillard G, Eybalin M, Lloyd R, Pujol R, Puel JL: Physiology, pharmacology and plasticity at the inner hair cell synaptic complex. Hear Res 2007;227:19–27.
  32. Sakata H, Kojima Y, Koyama S, Furuya N, Sakata E: Treatment of cochlear tinnitus with transtympanic infusion of 4% lidocaine into the tympanic cavity. Int Tinnitus J 2001;7:46–50.
  33. Salt AN, Plontke S: Local inner-ear drug delivery and pharmacokinetics. Drug Discov Today 2005;10:1299–1306.
  34. Tyler RS, Oleson J, Noble W, Coelho C, Ji H: Clinical trials for tinnitus: study populations, designs, measurement variables, and data analysis. Prog Brain Res 2007;166:499–509.
  35. Vesterager V: Tinnitus – Investigation and management. BMJ 1997;7082:728–731.